Citations

Clear

41 citation(s) found for "Cowan, Andrew J".

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
Wechalekar, Ashutosh , Sanchorawala, Vaishali , Zepeda, Victor H. Jimenez-, Suzuki, Kenshi, Lentzsch, Suzanne , Huart, Antoine , Carpinteiro, Alexander , Swenson, Eugene , Khan, Zilehuma, Catini, Julia, Kulkarni, Hrishikesh, Meltzer, Brian, Lake, Stephen, Liedtke, Michaela , Investigators, for the CARES, Ting, Stephen Bek Ngie, Mollee, Peter Norman, Meuleman, Nathalie, Delforge, Michel, Zepeda, Victor Jimenez, Zhang, Shuyang, Du, Xin, Wang, Jianan, Qian, Honglan, Sun, Chunyan, Belhadj, Karim , Arnulf, Bertrand, Karlin, Lionel, Macro, Margaret, Colella, Jean-Marc Schiano De, Stoppa, Anne-Marie, Viallard, Jean-Francois, Fenk, Roland, Hansen, Timon, Girke, Vera, Nogai, Axel, Gatt, Moshe, Lavi, Noa, Magen, Hila , Palladini, Giovanni, Pane, Fabrizio, Buda, Gabriele , Ishida, Tadao, Iida, Shinsuke, Jamroziak, Krzysztof, Byun, Jamin, Koh, Youngil, Kim, Kihyun, Villamediana, Ramón Lecumberri, Lopez, Maria Teresa Cibeira, Martínez, Irene Romera, Duarte, Rafael , Castello, Isabel Angela Krsnik, Garcia, Maria Esther Gonzalez , Chacon, Eusebio Narciso Martin, Martínez, Javier Alberto Rojas , Valent, Jason , Rosenzweig, Michael A., Chung, Alfred, Wong, Sandy, Bumma, Naresh , Comenzo, Raymond, Gaballa, Mahmoud, Lee, Hans C., Kaufman, Gregory P., Passero, Frank, Stockerl-Goldstein, Keith, Waxman, Adam, D'Souza, Anita, Cowan, Andrew, Lee, Sarah, Libby, Edward, Godara, Amandeep , Kovacsovics, Tibor, Sengsayadeth, Salyka, Goodman, Stacey , Chaulagain, Chakra, Wechalekar, Ashutosh D. , Dispenzieri, Angela , Sanchorawala, Vaishali , Kastritis, Efstathios , Lentzsch, Suzanne , Meltzer, Brian , Liedtke, Michaela , Dispenzieri, Angela , Kastritis, Efstathios , Bhutani, Divaya , Bianchi, Giada , Suzuki, Kenshi , Khan, Zilehuma, Kulkarni, Hrishikesh, Lake, Stephen, Ting, Stephen B. , Mollee, Peter , Agis, Hermine , Straßl, Irene , Meuleman, Nathalie , Delforge, Michel , Sedlák, František , Jaccard, Arnaud , Arnulf, Bertrand , Karlin, Lionel , Macro, Margaret , Stoppa, Anne‐Marie, Bridoux, Frank , Chalopin, Thomas , Viallard, Jean‐François , Fenk, Roland , Symeonidis, Argiris , Annibali, Ombretta , Iida, Shinsuke, Ikezoe, Takayuki , Jamroziak, Krzysztof , Koh, Youngil, López, Maria Teresa Cibeira, Rios, Rafael, Garcia, Maria Esther Gonzalez, Chacón, Eusebio Martín, Valent, Jason Neil , Rosenzweig, Michael, Comenzo, Raymond L. , Gaballa, Mahmoud , Kaufman, Gregory P., Medvedova, Eva , Passero, Frank Charles , Stockerl-Goldstein, Keith , Chaulagain, Chakra P.

Mayo Clinic

Journal of Clinical Oncology | May 29, 2026 | Volume: 44 | Issue: 20 | Pages: 1899-1910

10.1200/jco-26-00755 | PMID 42212672 Get It

PURPOSE In immunoglobulin light chain (AL) amyloidosis, amyloid fibrils cause organ dysfunction. Anselamimab, a monoclonal antibody, selectively binds to amyloid fibrils, accelerating their clearance. METHODS Newly diagnosed patients with European modification of Mayo 2004 stage IIIa or IIIb AL amyloidosis were randomly assigned to receive anselamimab or placebo with cyclophosphamide, bortezomib, and dexamethasone (with or without daratumumab). The primary end point was a hierarchical composite of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalizations (CVHs), analyzed using the Finkelstein-Schoenfeld test and win ratio estimation. RESULTS Among 406 randomly assigned patients, the primary end point win ratio for anselamimab versus placebo was 1.11 (95% CI, 0.83, 1.50; P = .332) and the hazard ratio (HR) for ACM was 0.80 (95% CI, 0.57, 1.13; P = .290). CVH rates in the anselamimab and placebo groups were 0.59 (95% CI, 0.42, 0.83) and 0.89 (95% CI, 0.55, 1.43), respectively ( P = .145). Among patients with kappa isotype (n = 72), the win ratio was 2.06 (95% CI, 0.98, 4.31; P = .100) and anselamimab reduced ACM by 62% versus placebo (HR, 0.38; 95% CI, 0.17 to 0.86; nominal P = .012), and CVH by 71% (IRR, 0.29; 95% CI, 0.10 to 0.87; nominal P = .028) with improvements in Kansas City Cardiomyopathy Questionnaire-Overall Score. There was no clinical benefit observed in the lambda population. Anselamimab was generally well-tolerated; safety data were comparable between treatment arms overall. CONCLUSION Treatment with anselamimab, an antifibril antibody used alongside antiplasma cell dyscrasia therapy, while not meeting the primary end point in the overall population, significantly improved ACM and CVH in patients with kappa AL, potentially offering a new therapeutic option for this isotype.
Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
Ren, Zexin , Zhao, Zixuan , Cowan, Andrew J, Ma, Will , Xie, En , Shi, Qian, Shi, Qian , Cowan, Andrew J , Xie, En , Shi, Qian , Cowan, Andrew J.

Mayo Clinic

Cancer Research Communications | May 2, 2026 | Volume: 6 | Issue: 5 | Pages: 1206-1212

10.1158/2767-9764.crc-25-0393 | PMID 42068235 Get It

Abstract Minimal residual disease (MRD) has been endorsed by the FDA Oncology Drugs Advisory Committee as an endpoint for accelerated approval in multiple myeloma based on individual patient data collected from randomized trials. However, emerging data from recent trials were not included. A novel artificial intelligence (AI)–assisted framework is proposed, which automates information identification and extraction, providing up-to-date analyses that confirm moderate trial-level and strong individual patient–level associations between MRD− rates at suspected complete response (MRD-CR) and survival endpoints in multiple myeloma. Specifically, this study utilized an AI-assisted framework that identifies relevant studies and filters critical information to analyze published data via 2 independent objectives. First, we examined the trial-level association using the coefficients of determination (R2) and its 95% confidence intervals (CI) based on published statistics of treatment effects on MRD and various endpoints. Next, we generated synthetic individual patient data with covariates through AI-curated tools to estimate the individual-level association. The AI tool searched for eligible randomized clinical trials (RCT). A total of 20 two-arm comparisons from 19 RCTs were analyzed. Trial-level analysis showed an R2 of 0.71 (95% CI, 0.52–0.89) pooling disease subpopulations. Furthermore, AI techniques were applied to create synthetic individual data, combining information extracted from Kaplan–Meier curves and subgroup analyses from published literatures. Using generated synthetic data, we estimated the individual-level correlation between MRD-CR rates and progression-free survival outcomes with a bivariate copula model and calculated a global odds ratio of 7.28 (95% CI, 5.60–8.95). Significance: (i) A novel AI-assisted framework is proposed, which automates information identification and extraction, providing rapid up-to-date analyses. (ii) Moderate trial-level and strong individual patient–level associations between MRD and various clinical endpoints in multiple myeloma are confirmed.
Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data
Goel, Utkarsh , Dragomirescu, Catalin , Zanwar, Saurabh , Cassano, Rafaella Cassano, Cicero, Kara I. , Cowan, Andrew J., Banerjee, Rahul, Anwer, Faiz , Khouri, Jack , Cowan, Andrew J , Anwer, Faiz , Cowan, Andrew J. , Banerjee, Rahul , Dima, Danai

Mayo Clinic

British Journal of Haematology | April 23, 2026 | Volume: 208 | Issue: 6 | Pages: 2134-2142

10.1111/bjh.70490 | PMID 42023513 Get It

Summary Functional high‐risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12–24 months of front‐line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front‐line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less effective front‐line therapy. In this study, we combined data from three Center for International Blood and Marrow Transplant Research studies (MM18‐02, MM19‐01 and MM20‐03). We included patients who received front‐line AHSCT between 2008 and 2018 and had progression <12 (FHR12, n = 465), <18 (FHR18, n = 672) or <24 months (FHR24, n = 853) after AHSCT. We classified induction therapy as standard lenalidomide‐containing triplets (bortezomib, lenalidomide, dexamethasone [VRD]/carfilzomib, lenalidomide, dexamethasone [KRD]) versus other (bortezomib, thalidomide, dexamethasone [VTD]/bortezomib, cyclophosphamide, dexamethasone [VCD]/bortezomib, dexamethasone [VD]/lenalidomide, dexamethasone [RD]) and studied the impact of front‐line therapy on post‐FHR overall survival (OS). In the FHR12 cohort (follow‐up 48 months), the OS after VRD/KRD ( n = 238) was 21 versus 17 months with other regimens ( n = 227, hazard ratio [HR] = 1.2, 95% confidence interval [CI]: 0.6–1.06). In a multivariable model, the HR for OS was 0.94 (95% CI: 0.7–1.3, p = 0.69) for VRD/KRD versus other regimens. There was no significant interaction between type of first‐line (1L) therapy and time from 1L AHSCT to first relapse in predicting OS. Similar results were seen for FHR18 and FHR24. FHRMM remains a negative prognostic factor irrespective of front‐line therapy and warrants consideration of T‐cell engagers' second‐line therapy.
Idecabtagene vicleucel manufacturing and clinical value of out-of-specification products in relapsed and refractory MM
Sidana, Surbhi , Lin, Yi , Cowan, Andrew J , Rodriguez-Otero, Paula, Scheid, Christof , Müeller, Peter, Broussard, Connor, Krengel, Peter, Li, Yun, Piault, Romain, Corrao, Amy, Ho, Christine, Patel, Krina K., Lin, Yi , Rodríguez‐Otero, Paula , Lin, Yi , Rodriguez-Otero, Paula , Patel, Krina , Sidana, Surbhi , Scheid, Christof , Cowan, Andrew J. , Mueller, Peter J., Patel, Krina K.

Mayo Clinic

Blood Advances | March 27, 2026 | Volume: 10 | Issue: 11 | Pages: 3769-3776

10.1182/bloodadvances.2025017186 | PMID 41894689 Get It

Abstract Idecabtagene vicleucel (ide-cel) is a chimeric antigen receptor (CAR) T-cell therapy approved for relapsed and refractory multiple myeloma (RRMM). Out-of-specification (OOS) CAR T cells not meeting criteria for commercial release are considered an investigational product; the expanded access protocol (EAP) allows release of OOS product for administration. The manufacturing analysis of capability, reliability, and timely delivery of ide-cel in the United States over &gt;3 years since its approval included patients with RRMM who underwent leukapheresis for ide-cel treatment after ≥2 prior lines of therapy between 23 February 2021 and 1 November 2024. Additionally, the BB2121-EAP-001 study evaluated safety and efficacy of OOS ide-cel and included patients who had undergone leukapheresis for commercial ide-cel treatment not meeting commercial release specifications, most commonly due to high CD137 activation or low-infused dose. Primary end point was safety. Secondary end points were overall response rate (ORR) and complete response rate (CRR). At data cutoff (1 November 2024), the manufacturing success rate of ide-cel improved from 95.3% in 2021 to 96.8% in 2024. Turnaround time also improved from 31 days in 2021 to 24 days in 2024. In BB2121-EAP-001, 68 (72.3%) patients experienced ≥1 cytokine release syndrome event (mostly grade 1/2) and 15 (16.0%) had neurological toxicities (2 grade 3, 13 grade 1/2). ORR was 75.4% (95% confidence interval [CI], 63.1-85.2), and CRR was 35.4% (95% CI, 23.9-48.2). The manufacturing success of ide-cel is reliable and consistently high, and when OOS ide-cel products emerged, they demonstrated consistent clinical efficacy and safety. The BB2121-EAP-001 study was registered at www.clinicaltrials.gov as NCT04771078.
Preferred standard‐of‐care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists
Banerjee, Rahul, Dong, Sharlene , McCaughan, Georgia , Mehra, Nikita , Wang, Bo, Sperling, Adam S. , Cowan, Andrew J., Anderson, Lee, Rajkumar, S. Vincent, Rajkumar, S. Vincent , Banerjee, Rahul , Banerjee, Rahul , Rajkumar, S Vincent , Sperling, Adam S , Cowan, Andrew J. , Anderson, Larry D. , Kaur, Gurbakhash

Mayo Clinic

British Journal of Haematology | March 17, 2026 | Volume: 208 | Issue: 5 | Pages: 1831-1835

10.1111/bjh.70435 | PMID 41841734 Get It

Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab‐Treated Patients
Mellgard, George , Bazarbachi, Abdul-Hamid, Zanwar, Saurabh , Hegenbart, Ute , Bodanapu, Geethika , Bhutani, Divaya , Chen, G., D'Souza, A, Dispenzieri, Angela, Gertz, Morie, Kumar, Shaji, Lentzsch, Suzanne , Milani, Paolo, Muchtar, E., Palladini, Giovanni, Trajanova, Despina, Patwari, Anannya , Sanchorawala, Vaishali, Mohty, Mohamad, Wang, Shikun , Kastritis, Efstathios, Theodorakakou, Foteini, Cowan, Andrew J, Gertz, Morie A. , D’Souza, Anita , D'Souza, Anita , Gertz, Morie A , Palladini, Giovanni , Sanchorawala, Vaishali , Kastritis, Efstathios , Theodorakakou, Foteini , Chakraborty, Rajshekhar , Hegenbart, Ute , Bhutani, Divaya , Bazarbachi, Abdul Hamid , Dispenzieri, Angela , Milani, Paolo , Muchtar, Eli , Mohty, Mohamad , Kastritis, Efstathios , Theodorakakou, Foteini , Schönland, Stefan , Chakraborty, Rajshekhar

Mayo Clinic

American Journal of Hematology | March 8, 2026 | Volume: 101 | Issue: 4 | Pages: 768-783

10.1002/ajh.70257 | PMID 41793153 Get It

ABSTRACT Systemic AL amyloidosis is a clonal plasma cell dyscrasia, where toxic free light chains (FLCs) lead to vital organ damage, with risk of early mortality despite effective therapies. Notably, there is a paucity of data on the incidence and predictors of early mortality in the daratumumab (Dara) era. We conducted a multi‐center retrospective cohort study to develop and validate a risk‐prediction model for early mortality (all‐cause death within 6 months) in patients treated with Dara‐based frontline regimens. We used univariate analysis to identify covariates for a logistic regression model predictive of 6‐month mortality and generated a clinical risk score. Among 339 patients across eight centers, 36 (10.6%) experienced early mortality. Multivariate analysis identified four independent predictors: NT‐proBN P > 5300 pg/mL (odds ratio [OR] 3.83, p = 0.006), A ge > 75 years (OR 2.96, p = 0.073), absence of t(11;14) on C ytogenetics (OR 3.0, p = 0.022), and E COG performance status (OR 1.72 per unit increase, p = 0.044). The resulting PACE score stratified patients into three risk groups with a 6‐month mortality of 1.2% (low‐risk), 11.7% (intermediate‐risk), and 50.0% (high‐risk). The PACE score demonstrated superior discrimination (C‐index 0.78) for early mortality compared to Mayo 2004 (0.69) and Mayo 2012 (0.55) staging systems. External validation confirmed robust discrimination (C‐index 0.73) with corresponding 6‐month mortality rates of 4.2%, 15.25%, and 37.04% across respective risk groups. The PACE score provides a clinically applicable tool for early mortality risk stratification in AL amyloidosis patients receiving Dara‐based therapy, and will enable improved patient counseling, clinical trial design, and identification of ultra‐high‐risk patients requiring intensive monitoring and novel therapies.
Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era
Bazarbachi, Abdul‐Hamid , Zanwar, Saurabh , Trajanova, Despina, Gertz, Morie A., Dispenzieri, Angela, Kumar, Shaji, D'Souza, A, Patwari, Anannya , Cowan, Andrew, Chen, GuiZhen, Milani, P. , Palladini, Giovanni, Bodanapu, Geethika , Mohty, M, Lentzsch, Suzanne , Muchtar, E., Bazarbachi, Abdul Hamid , Chakraborty, Rajshekhar , Hegenbart, Ute , Bhutani, Divaya , Gertz, Morie A. , Dispenzieri, Angela , D’Souza, Anita , Milani, Paolo, Sanchorawala, Vaishali , Mohty, Mohamad , Schönland, Stefan , Muchtar, Eli , Chakraborty, Rajshekhar

Mayo Clinic

HemaSphere | December 29, 2025 | Volume: 9 | Issue: 12 | Pages: No page available

10.1002/hem3.70276 | PMID 41473002 Get It

Abstract Rapid and profound reduction of free light chains (FLCs) improves outcomes in AL amyloidosis; however, early FLC kinetics with daratumumab‐based frontline therapy remain undefined. We retrospectively analyzed 315 patients treated with daratumumab–bortezomib–cyclophosphamide–dexamethasone (Dara–VCd) or Dara–Vd at eight centers. Involved FLC (iFLC), the difference between iFLC and uninvolved FLC (dFLC), and hematologic response (≥very good partial response [VGPR]) were assessed at baseline and at 1, 3, and 6 months, and correlated with light chain isotype, disease burden (bone‐marrow plasma‐cell percentage [%BMPC], baseline dFLC), and cytogenetics. Hematological ≥VGPR increased from 49.8% at 1 month to 66.0% at 3 months. The kappa isotype showed slower responses, with higher iFLC/dFLC and lower ≥VGPR at each time point compared to lambda. Higher %BMPC or baseline dFLC predicted persistently elevated iFLC/dFLC and reduced ≥VGPR. The t(11;14) translocation was associated with lower baseline FLC but similar subsequent kinetics. BMPC < 10% and dFLC < 18 mg/dL independently predicted early ≥VGPR (in ≤1 month). Early ≥VGPR conferred superior hematologic event‐free survival (heme‐EFS) and overall survival (OS) versus later responders (P < 0.001). At a 3‐month landmark, achieving dFLC < 1 mg/dL further stratified prognosis, conferring longer heme‐EFS and OS (P < 0.01). Frontline Dara‐based therapy elicits rapid, deep responses in AL amyloidosis; early ≥VGPR (within 1 month) and dFLC < 1 mg/dL by 3 months predict durable EFS and OS, whereas higher baseline disease burden delays hematologic response.
Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis
Popat, Rakesh , Morjaria, Oliver, Tan, Carlyn , Bal, Susan , Nagarajan, Chandramouli, Htut, Myo, Dave, Mrugakshi, Cowan, Andrew J. , Mian, Hira , Mian, Hira , Popat, Rakesh , Usmani, Saad Z. , Visram, Alissa , Costa, Luciano J. , Hájek, Roman , Mihalyova, Jana , Martinez-Lopez, Joaquin , Sáez, Adolfo , Dimopoulos, Meletios Α. , Kastritis, Efstathios , Nagarajan, Chandramouli , Chung, Shimin Jasmine , Htut, Myo , Chng, Wee Joo , Tso, Allison , Martin, Thomas G. , Huang, Chiung‐Yu , Einsele, Hermann , Lin, Yi

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4588-4588

10.1182/blood-2025-4588 Get It

Abstract Introduction: Elranatamab (Elra) is a bispecific antibody (BsAb) targeting BCMA that is approved for patients with triple class exposed relapsed refractory myeloma (RRMM) on the basis of the MagnetisMM-3 phase 2 trial. For BCMA naïve patients, an overall response rate (ORR) of 61.0% and median progression free survival (PFS) of 17.2m was observed with a median overall survival (OS) of 24.6m. However, efficacy and safety information in the real world is lacking. Methods: This was an international retrospective study of patients with RRMM treated with Elra monotherapy outside of clinical trials. Data was collected through the International Myeloma Foundation Immunotherapy Database from 7 countries (UK, USA, Canada, Greece, Spain, Czech Republic and Singapore). High-risk cytogenetic abnormalities (HRCA) were defined as 1q+, t(4;14), t(14;16), t(14;20), and/or del(17p). Response was assessed using IMWG consensus criteria. Patient characteristics were summarized by frequency (percentage) or median (range). PFS, OS were evaluated using the Kaplan-Meier method and reported with 95% confidence intervals. Results: 79 patients were included. Median age was 67 years (range: 41-95y) with 20% ≥75 years. Racial distribution was: 75% White, 16% Black/African American, 8% Asian/Pacific. 55% were ECOG performance status (PS) 1-2. Patients received a median of 5 prior lines (range 1-11), and 35% were BCMA exposed (9% CAR-T, 5% ADC, 7% BsAb, 8% BsAb plus CAR-T, 4% ADC plus BsAb). Of those with available data, 45% had HRCA,13% had extramedullary disease (EMD) and 32% had penta-drug refractory RRMM. Overall, 48% would not have been eligible for the MagnetisMM-3 trial. Median follow-up was 6.3m (range 0.5-35.0). ORR was 53% (PR 11%, VGPR 33%, CR 8%, sCR 1%) and 67% for BCMA naïve patients. Responses were significantly lower for BCMA exposed patients (ORR 31%) but did not differ by age (51% &lt;75yrs vs 60% ≥75yrs). On univariate analysis, prior BCMA exposure, platelets &lt;50, presence of HRCA and penta-refractoriness were significantly associated with a lower response rate. PFS for the whole cohort at 6 and 12m was 64% (95%CI, 54-77%) and 52% (40-67%); for BCMA naïve patients, it was 77% (65-90%) and 67% (54-84%), respectively. Within the whole cohort, PFS was shorter for: BCMA exposed (median 4.0m vs not reached (NR)), platelets &lt;50 (2.0 vs 21.7m), HRCA (7.2m vs NR), penta-refractory (4.3m vs NR). PFS did not differ significantly by EMD, PS, age, or creatinine clearance. OS for the whole cohort at 6 and12m was 74% (64-85%) and 58% (45-74%); for BCMA-naïve patients, it was 80% (43-85%) and 70% (57-87%), respectively. Within the whole cohort, OS was shorter for: BCMA exposed (median 10.3m vs NR), platelets &lt;50 (4.3m vs NR), HRCA (10.7m vs NR) and penta-refractory (10.3m vs NR). Univariate regression analysis demonstrated that prior BCMA exposure, platelets &lt;50 and penta-refractoriness were significantly associated with a worse PFS and OS, and HRCA predicted poorer survival CRS was observed in 41% of patients (grade(G)1: 35%, G2: 5%, ≥G3: 0%) with most occurring with the first step up dose (SUD): SUD1: 29%, SUD2: 15%, full dose: 4%. Tocilizumab was used in 20% and steroids in 3%. ICANS was observed in 4 cases (5%): G1: 2, G2: 1, G4: 1. Treatment was with steroids (n=3) and tocilizumab (n=2). G3-4 thrombocytopenia was observed in 19% and 14% required platelet transfusions. G3-4 neutropenia occurred in 25% with overall 31% requiring GCSF. Infections were reported in 33 (42%) patients with median time to infection of 41 days. A total of 94 infection episodes were observed over 581 personal months. There were 2 infection-related deaths reported (1 had IVIG, 1 did not). 64% had hypogammaglobulinemia (IgG &lt; 400mg/dl) and IVIG was given in 65% of patients. Conclusions: In this first international real world analysis, Elranatamab achieved a response rate of 67% and a 12m PFS of 67% in BCMA naïve patients, similar to the MagnetisMM-3 trial despite almost half not meeting trial eligibility. However, prior BCMA exposure, platelets &lt;50, high risk cytogenetics and penta refractory status were predictors of poorer outcomes. Acknowledgements: The International Myeloma Foundation, International Myeloma Working Group (IMWG)
Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age
Voorhees, Peter M. , Cohen, Yaël C. , Lindsay, Jindriska, Suzuki, Kenshi , Beksaç, Meral , Magen, Hila , Garate, Gonzalo, Theunissen, Koen, Mylin, Anne K., Hallam, Simon , Bringhen, Sara, Uttervall, Katarina , Ye, J Christine, Cowan, Andrew J. , Mateos, María‐Victoria , Goldschmidt, Hartmut , Vieyra, Diego, Raval, Ashta, Sha, Linlin, Rousseau, Els, Dennis, Robyn M., Carson, Robin, Dimopoulos, Meletios Α. , Schjesvold, Fredrik , Hungria, Vânia , Sandhu, Irwindeep , Baker, Ross , Kosugi, Hiroshi , Levin, Mark-David , Stockerl‐Goldstein, Keith , Oriol, Albert , Mikala, Gábor , Špıčka, Ivan , Bringhen, Sara, Puła, Bartosz , Khan, Abdullah , Medvedova, Eva , Moreau, Philippe, Raval, Ashta, Li, Liang , Carson, Robin, Rajkumar, S. Vincent

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 372-372

10.1182/blood-2025-372 Get It

Abstract Introduction : Current standard of care for smoldering multiple myeloma (SMM), an asymptomatic precursor of multiple myeloma (MM), is observation until progression to active MM. Increasing evidence suggests that patients (pts) with SMM at high risk for progression to active MM may benefit from early treatment (tx). In AQUILA, a phase 3 study in pts with high-risk SMM (NCT03301220), daratumumab (Dara) monotherapy significantly reduced risk of progression to active MM or death with a trend of extending overall survival (OS) vs active monitoring (ActMon), with no new safety concerns. Given the evolution in SMM risk stratification, a post hoc analysis was performed to assess outcomes using the IMWG 2020 and IMWG 2020 plus cytogenetic risk models to assess which AQUILA pts benefited most from Dara monotherapy. Safety and efficacy analysis by age and stem cell collection outcomes were also assessed. Methods: Eligible pts with a confirmed diagnosis (≤5 y) of high-risk SMM per IMWG 2014 criteria, defined as clonal bone marrow plasma cells (BMPC) ≥10% and ≥1 risk factor (IgA SMM, serum protein ≥30 g/dL, serum involved:uninvolved free light chain [I/U FLC] ratio ≥8 and &lt;100, immunoparesis with reduction of 2 uninvolved Ig isotypes, and/or clonal BMPC &gt;50% to &lt;60%) at study entry, were randomized 1:1 to receive subcutaneous Dara or ActMon for 39 cycles, 36 months, or until confirmed disease progression (PD), whichever came first. Primary endpoint was progression-free survival (PFS) assessed by independent review committee, defined as progression to active MM (based on IMWG SLiM-CRAB diagnostic criteria) or death. Secondary endpoints included time to first-line (1L) MM tx and OS. For this post hoc analysis, we assessed outcomes by age, IMWG 2020 high-risk SMM criteria (BMPC &gt;20%, monoclonal spike &gt;2 g/dL, serum FLC ratio &gt;20; ≥2 factors=high risk; also known as the Mayo 2018 or the 20-2-20 criteria), and the IMWG 2020 plus cytogenetic criteria (IMWG 2020 criteria + presence of ≥1 high-risk cytogenetic abnormalities [t(4;14), t(14;16), +1q and/or del13q]; ≥3 factors=high risk). Results : Dara tx showed a PFS benefit across all IMWG 2020 risk subgroups (low: hazard ratio [HR], 0.59; intermediate: HR, 0.70), with the largest benefit in the high-risk subgroup, where the PD/death rate in the ActMon arm was ~1.6-fold that in the Dara arm (62.8% vs 37.5%; HR, 0.36). This benefit of Dara vs ActMon was preserved over time, with 5-year PFS rates of 78.2% vs 71.6%, 56.2% vs 42.9%, and 60.4% vs 23.6% in IMWG 2020 low-, intermediate-, and high-risk groups, respectively. There was a positive trend favoring Dara for time to 1L MM treatment across all IMWG 2020 risk groups (low-risk HR, 0.63; 95% CI, 0.22–1.80; intermediate-risk HR, 0.57; 95% CI, 0.35–0.92; high-risk HR, 0.39; 95% CI, 0.25–0.62). IMWG 2020 plus cytogenetic risk classification results will be available at the time of presentation. When comparing the younger (&lt;65y HR, 0.51; 95% CI, 0.32–0.79) vs the older (≥65y, HR, 0.50; 95% CI, 0.32–0.77) pt population, a PFS benefit was observed regardless of age. Similarity was also observed in TEAE incidence rate when looking into &lt;65, 65 to &lt;75, and ≥75 y subgroups (82.7%, 81.1%, and 87.5% with ActMon; 96.2%, 98.5%, and 95.2% with Dara); however, serious TEAEs were more frequently observed in older ActMon pts (12.2%, 18.9%, and 50.0% with ActMon; 24.8%, 35.8%, and 28.6% with Dara). Across all pts treated/monitored in AQUILA, 23 (11.9%) and 41 (20.9%) pts in the Dara and ActMon arms, respectively, received autologous stem cell transplant as part of their first tx after progressing to active MM, with very limited plerixafor use (Dara, 3 [1.6%] vs ActMon, 9 [4.6%]). Median (range) CD34+ cell yield was 5.0 (2–20)×106 cells/kg body weight among 22 pts in the Dara arm and 5.1 (2–21)×106 cells/kg body weight among 39 pts in the ActMon arm. Conclusions : In this analysis, pts with high-risk SMM from the phase 3 AQUILA study treated with Dara monotherapy experienced long-term PFS benefit across IMWG 2020 subgroups, with the most pronounced benefit in the high-risk subgroup. No notable differences in PFS or safety were observed across age subgroups. Early Dara tx for high-risk SMM did not have a detrimental impact on stem cell yield. Although mature OS analyses are forthcoming, overall, these results further support early intervention with Dara monotherapy vs ActMon among pts with high-risk SMM, regardless of risk stratification criteria used.
Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis
Huart, Antoine , Landau, Heather , Iida, Shinsuke , Motorna, Olga , Ishida, Tadao, Bhutani, Manisha, Cowan, Andrew J., Rosenberg, Tanya, Motte-Mohs, Ross La, Wang, Fan , Hoffman, David, Arriola, Emma, Yu, Jovian , Kumar, Shaji, Palladini, Giovanni, Chakraborty, Rajshekhar , Kastritis, Efstathios , Jaccard, Arnaud , Mollee, Peter , Ishida, Tadao , Kawano, Yawara , D’Souza, Anita , Hoffman, James, Talati, Chetasi , Motte‐Mohs, Ross La, Fei, Mingwei , Kumar, Shaji , Dispenzieri, Angela , Sanchorawala, Vaishali

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 692-692

10.1182/blood-2025-692 Get It

Abstract Background B-cell maturation antigen (BCMA)-targeting immunotherapies represent a promising class of treatment for the management of immunoglobulin light chain (AL) amyloidosis, a disease that is related to clonal plasma cells. Etentamig is a 2nd generation, off-the-shelf, fully human BMCA X CD3 bispecific antibody with bivalent BCMA domain and low CD3 affinity that targets both BCMA-expressing plasma cells and CD3-expressing T cells. Etentamig monotherapy is being studied in multiple myeloma (MM) in an ongoing phase 3 study (NCT06158841). Here, we report the first safety and efficacy results from M24-209, an open-label phase 1/2 study evaluating etentamig monotherapy in patients (pts) with relapsed/refractory (RR) AL amyloidosis from dose level 1 (DL1). Methods The phase 1 dose escalation (ESC) portion of the study (NCT06158854) with etentamig enrolled pts with RR AL amyloidosis with ≥1 prior lines of therapy (LOT), including a proteasome inhibitor and an anti-CD38 monoclonal antibody with no prior BCMA exposure. Eligible pts were required to have a difference in involved and uninvolved serum free light chain (dFLC) of ≥50 mg/L, and pts with Mayo Clinic 2004 cardiac risk stage IIIb with NT-proBNP ≥8500 pg/ml were excluded. Three dose groups were explored in dose ESC (etentamig dose levels [DL] 1, 2, and 3). In all cohorts, pts will receive up to 24 cycles of treatment and will be followed until disease progression. In dose ESC, the primary objectives are to determine safety/tolerability, pharmacokinetic/pharmacodynamic, and recommended phase 2 dose. The secondary objectives include evaluation of efficacy as measured by hematologic response and organ response. Responses are investigator assessed per consensus guidelines (Comenzo, et al. Leukemia. 2012. 26[11]:2317-25; Palladini G, et al. Amyloid. 2021 [Epub];28[1]:1-2). Results As of 17 July 2025, all DLs in dose ESC have been fully enrolled, and 12 pts have been treated with etentamig at DL1. Due to short follow-up, this initial report only includes data from DL1, with further follow-up data from ESC to be included at the time of presentation. Median duration of follow up in DL1 was 9.4 months (8.3–13.8) with 83% of pts continuing treatment. Median age for pts was 72 years (range, 56–85 years). Median number of prior LOT was 2 (range, 1–6), and median time from initial diagnosis was 3.6 years. Thirty-three percent have received a prior stem cell transplant and 50% previously received the regimen of daratumumab with cyclophosphamide, bortezomib, and dexamethasone in combination. Median dFLC at study baseline was 110. 5 mg/L (range, 56.6–617.5). At baseline, 83% of pts had cardiac involvement, 25% had renal involvement, and 8% had hepatic involvement. Eighty-three percent of pts had lambda AL amyloidosis. Treatment-emergent adverse events were reported in 100% (42% Grade ≥3) of pts at DL1. Cytokine release syndrome (CRS) occurred in 2 pts (17%, all Grade 1), with no instances of any grade immune effector cell-associated neurotoxicity syndrome (ICANS). CRS occurring after the first dose had median time to onset of 6.8 hours (range, 6.7–6.9). Grade ≥3 infections occurred in 1 pt (8%, all Grade 3). Grade ≥3 neutropenia also occurred in 1 pt (8%, all Grade 3), and no Grade ≥3 events of thrombocytopenia or anemia occurred. No Grade 5 events have occurred. Within the dose ESC DL1 cohort, the overall hematologic response rate was 100%, with all pts achieving ≥VGPR and 83% of pts achieving complete response (CR). The median time to CR was 0.9 months (0.3–9.3). The median duration of response has not yet been reached and 100% of pts remain in their best overall response by investigator assessment. To date, no pts have experienced hematologic progression on study. Cardiac response was observed in 30% of evaluable pts. Renal response was seen in 67% of evaluable pts. Conclusions In the DL1 cohort, etentamig showed a manageable safety profile in AL amyloidosis with low incidence and severity of CRS, no ICANS, and limited Grade ≥3 cytopenia events. Deep and rapid hematologic responses were observed with 100% ≥VGPR rate and 83% hematologic CR rate. Additional dose-level data will be presented at the time of the meeting. All pts remain in ongoing follow-up and evaluation, and the study will begin the dose expansion (EXP) portion after dose selection.